VIVENTIA PROVIDES UPDATE FOR VICINIUM CLINICAL PROGRAM

Viventia Biotech announced that it has changed the name of its lead armed antibody, VB4-845, to Vicinium when the drug is used to treat bladder cancer. VB4-845 will continue to be known as Proxinium when it is used for the treatment of head and neck cancer. The company also announced it has expanded its ongoing Phase I/II bladder cancer trial for Vicinium, which remains on schedule, to include additional patients.

Vicinium is undergoing a Phase I/II clinical trial in Canada for the treatment of bladder cancer, with more than 40 patients enrolled to date in the Phase I dose-escalation stage. Following completion of this stage, anticipated to occur by the year's end, the Phase II arm will be initiated at the preferred dose level determined in the Phase I arm, and will include more than 30 patients.

Vicinium combines a cytotoxic protein payload with the highly precise tumor-targeting characteristics of a monoclonal antibody. A single molecule of the cytotoxic protein payload, Pseudomonas exotoxin, is capable of killing a cancer cell.